Company news
Halozyme Therapeutics, Inc. news in 2026
Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Halozyme Provides Update on German Preliminary Injunction Hearing
November 19, 2026
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
November 6, 2026
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
November 6, 2026
Halozyme reports third quarter 2026 results and raises full year 2026 financial guidance
November 5, 2026
Halozyme to Report Third Quarter 2026 Financial and Operating Results
October 22, 2026
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
October 7, 2026
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
October 6, 2026
Halozyme Announces Appointment of Jim Daly to its Board of Directors
September 30, 2026
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
September 17, 2026
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
September 16, 2026
Halozyme Appoints Dannielle Appelhans to its Board of Directors
August 18, 2026
Halozyme reports record second quarter 2026 results, beats estimates and raises full year 2026 financial guidance
August 6, 2026
Halozyme to Report Second Quarter 2026 Financial and Operating Results
July 23, 2026
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology
July 21, 2026
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
July 20, 2026
Halozyme Appoints David Ramsay as President Drug Delivery
June 30, 2026
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
June 15, 2026
Halozyme reports first quarter 2026 results and reiterates 2026 financial guidance
May 11, 2026
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
May 7, 2026
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
May 6, 2026
Halozyme to Report First Quarter 2026 Financial and Operating Results
April 30, 2026
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
April 30, 2026
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series ("ETF Series") and Exchange Traded Funds ("ETFs")
April 14, 2026
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
April 6, 2026
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
March 11, 2026
Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science
March 10, 2026
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
March 6, 2026
Russell Investments Expands Canadian ETF Lineup With Five New Offerings
February 18, 2026
Halozyme reports full year 2025 record revenue of $1.4 billion and reiterates strong 2026 Financial Guidance
February 17, 2026
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
February 10, 2026
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
January 28, 2026
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
January 20, 2026
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
January 7, 2026
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
January 4, 2026
Calls in 2026
- Halozyme Therapeutics (NASDAQ:HALO) Q3 2026 Earnings Call
Nov 5, 2026
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q2 2026 Earnings Call
Aug 6, 2026
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q1 2026 Earnings Call
May 11, 2026
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q4 2025 Earnings Call
Jan 28, 2026
Transcript
Decks in 2026
- Q3 2026 Earnings Presentation
Earnings · 14 slides · Nov 5, 2026
- Q2 2026 Earnings Presentation
Earnings · 15 slides · Aug 6, 2026
- Q1 2026 Earnings Presentation
Earnings · 17 slides · May 11, 2026
- FY2025 Earnings Presentation
Earnings · 18 slides · Feb 17, 2026
- Q4 2025 Earnings Presentation
Earnings · 26 slides · Jan 28, 2026